Want to see FR:NANO full AI Analyst Report?
NANO Stock Chart & Stats
€28.70
<€0.01(0.14%)
At close: 4:00 PM EST
€28.70
<€0.01(0.14%)
Day’s Range― - ―
52-Week Range€4.22 - €47.66
Previous CloseN/A
Volume30.64K
Average Volume (3M)654.19K
Market Cap
€1.58B
Enterprise Value€1.60B
Total Cash (Recent Filing)€52.75M
Total Debt (Recent Filing)€95.32M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Sep 30, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding50,619,583
10 Day Avg. Volume711,483
30 Day Avg. Volume654,186
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-10.94
Price to Sales (P/S)31.19
P/FCF Ratio-27.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€55.00Price Target Upside91.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€34.72M
Bulls Say, Bears Say
Bulls Say
Proprietary Platform & Big-partner Tie-upThe NBTXR3 nanoparticle platform plus a significant Janssen collaboration creates durable development and commercialization optionality. A large-pharma partner can fund trials, provide regulatory and commercial capabilities, and deliver milestone/royalty streams that de‑risk capital needs and speed market access over months to years.
High Reported Gross Margin In 2025A 100% gross margin in 2025 signals that reported revenue is largely partnership/licensing income or high-margin services. If sustained via collaborations or royalties, high gross margins provide operating leverage and capacity to fund SG&A and R&D efficiency, improving long-term profitability potential.
Collaboration/licensing-driven, Capital-efficient ModelA licensing/collaboration business model shifts material development costs to partners and generates milestone and royalty upside. For a ~97-employee clinical-stage firm, this model enables scalable program expansion without proportionate fixed-cost increases, improving capital efficiency over multiple quarters.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the company cannot self-fund development and will rely on external financing or partner payments. Over a 2–6 month horizon this raises dilution and financing execution risk, constrains program pacing, and limits strategic flexibility if markets tighten.
Negative Shareholders' Equity And Rising DebtNegative equity combined with increasing debt materially weakens financial flexibility and increases refinancing and covenant risk. This structural capital weakness can raise partner and lender costs, limit borrowing capacity, and heighten the chance of dilutive financings over the medium term.
Revenue Volatility And Inconsistent TrendsLarge swings and even a negative revenue year imply milestone timing or one-off accounting effects rather than stable recurring sales. That volatility undermines reliable forecasting, complicates partner negotiations and budgeting, and limits visibility into sustainable earnings power across quarters.
NANO FAQ
What was Nanobiotix SA’s price range in the past 12 months?
Nanobiotix SA lowest stock price was €4.21 and its highest was €47.66 in the past 12 months.
What is Nanobiotix SA’s market cap?
Nanobiotix SA’s market cap is €1.58B.
When is Nanobiotix SA’s upcoming earnings report date?
Nanobiotix SA’s upcoming earnings report date is Sep 30, 2026 which is in 70 days.
How were Nanobiotix SA’s earnings last quarter?
Currently, no data Available
Is Nanobiotix SA overvalued?
According to Wall Street analysts Nanobiotix SA’s price is currently Undervalued.
Does Nanobiotix SA pay dividends?
Nanobiotix SA does not currently pay dividends.
What is Nanobiotix SA’s EPS estimate?
Nanobiotix SA’s EPS estimate is -0.25.
How many shares outstanding does Nanobiotix SA have?
Nanobiotix SA has 50,619,583 shares outstanding.
What happened to Nanobiotix SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Nanobiotix SA?
Currently, no hedge funds are holding shares in FR:NANO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nanobiotix SA
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
NANO Stock 12 Month Forecast
Average Price Target
€55.00
▲(91.64% Upside)
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―